Stocktwits on MSN
Cathie Wood’s ARK made just one buy last session — and it’s a biotech stock up nearly 30% YTD
On Thursday, ARK bought a total of 56,769 shares of Intellia, with 48,178 shares purchased by its ARKK ETF and 8,591 shares ...
Earlier this month, Intellia Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, updating investors on its gene-editing pipeline and corporate progress. At ...
ATTR program on hold amid safety risks; HAE therapy faces tough rivals and small market. Read more analysis here.
The stock has lost significant market value since that debacle. While it's not clear that nex-z was responsible, it's also ...
Shares of Intellia Therapeutics NTLA have plunged 55.2% over the past three months.The steep decline follows a significant regulatory setback related to nexiguran ziclumeran (nex-z), NTLA’s lead ...
If you are wondering whether Intellia Therapeutics is attractively priced or still too expensive at around US$12.50, it helps to break the story into what the market has done recently and what the ...
Intellia Therapeutics' stock is downgraded to HOLD due to market skepticism and lack of near-term catalysts despite promising Phase 3 trials for HAE and ATTR. NTLA-2002, Intellia's CRISPR/Cas9 drug ...
PHILADELPHIA, PA / ACCESS Newswire / October 29, 2025 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the ...
Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results